. Author manuscript; available in PMC: 2017 Aug 7.

Published in final edited form as: Antivir Ther. 2015 Aug 11;21(1):55–64. doi: 10.3851/IMP2982

Table 2.

Resistance testing among virologic failures through Week 48

Subject ID	VF Week	VL at baseline, copies/mL	VL at VF confirmation, copies/mL	Genotype status	Resistance associated mutations
1	8	19,356	422	Below test threshold^a
2	8	195,146	190,339	Discontinued study treatment^b
3	8	848,845	82,432	Tested	E138K, Y181C, M230L, M184I, K219E, V75I
4	24	442,363	104	Below test threshold^a
5	24	10,823	110	Below test threshold^a
6	24	65,193	727	Missing^c
7	36	78,146	834	Tested	Y181C
8	36	83,096	244	Below test threshold^a
9	36	260,951	64	Below test threshold^a
10	48	37,177	53	Below test threshold^a
11	48	21,942	3129	Tested	E138K

VL: viral load, VF: virologic failure

Viral load below 500 copies/mL threshold specified by laboratory for genotype assay.

Participant developed rash and discontinued study treatment during Week 2.

Participant discontinued study participation, no sample available for genotype.